
    
      Prospective, randomized, unblinded clinical trial. Two groups of patients with glaucoma
      undergoing primary trabeculectomy or phaco-trabeculectomy with MMC between March 2009 and
      September 2012. The ranibizumab group (RAN) received 2 subconjunctival injections of 0.5 mg
      of ranibizumab (intraoperatively and on day 14) and he control group did not receive
      ranibizumab.
    
  